Pyxis Oncology Stock (NASDAQ:PYXS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.54

52W Range

$1.49 - $6.85

50D Avg

$2.99

200D Avg

$3.71

Market Cap

$100.50M

Avg Vol (3M)

$1.22M

Beta

1.28

Div Yield

-

PYXS Company Profile


Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

54

IPO Date

Oct 08, 2021

Website

PYXS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 24Jun 24Mar 24
Royalty$8.15M$8.15M$8.15M

Fiscal year ends in Dec 23 | Currency in USD

PYXS Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-82.20M$-123.48M$-69.72M
Net Income$-73.79M$-117.95M$-81.54M
EBITDA$-82.20M$-123.48M$-63.49M
Basic EPS$-1.85$-3.57$-9.60
Diluted EPS$-1.85$-3.57$-9.60

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
HOOKHOOKIPA Pharma Inc.
CRVSCorvus Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
CYTOAltamira Therapeutics Ltd.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
TERNTerns Pharmaceuticals, Inc.
OCEAOcean Biomedical, Inc.